An observational study in Opioid-induced Constipation, sponsored by BioDelivery Sciences International. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by BioDelivery Sciences International · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Opioid-Induced Constipation with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Opioid-Induced Constipation · United States.
Among the 43 studies in Opioid-Induced Constipation with a site in United States, this one is the only one that started in 2019, is one of 3 observational ones, and was the 43rd registered.
87 studies on the registry are indexed under Opioid-Induced Constipation; 6 are open to participants now.
Browse Opioid-Induced Constipation studies →1 of the 43 studies in Opioid-Induced Constipation with a site in United States is open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Opioid-Induced Constipation studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 20 · Phase 4 4
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34,532 is above the median of 385 across 18 observational studies indexed under Opioid-Induced Constipation.
Median enrollment 227 across the 40 interventional studies, 8,800 across the 3 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 43 have an industry lead sponsor. The 10 most frequent:
BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
BioDelivery Sciences International has 1 study filed under Opioid-Induced Constipation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Opioid-Induced Constipation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.
This is a prevalent new user cohort study conducted using multiple databases linkable to medical records and the National Death Index (NDI) to assess MACE risk among adult patients with chronic non-cancer pain receiving naldemedine or a comparator OIC medication. The uptake of naldemedine and comparator OIC medications will be monitored for each database annually until a sufficient number of patients to support the comparative analyses in the safety assessment phase is accrued. The safety assessment phase will commence at the conclusion of the monitoring phase.
The study population will include new users of naldemedine or one of the comparator OIC medications (lubiprostone or naloxegol) who satisfy all of the inclusion criteria and none of the exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
Drug: Naldemedine
Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
Drug: Lubiprostone
Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
Drug: Naloxegol
0.2 mg tablet once a day at any time with or without food
Also known as: Symproic®
0.024 mg twice a day \[adjust dose based on liver function\]
Also known as: Amitiza®
25 mg tablet once a day in morning, 1 hour before or 2 hours after food
Also known as: Movantik®
Number of Participants with a Major Adverse Cardiovascular Event
A composite of major adverse cardiovascular events, cardiovascular (CV) death, nonfatal myocardial infarction (MI), and non-fatal stroke; participants with major adverse cardiovascular events will be identified using claims data and the national death index.
Time frame: 5 years
Number of Participants with Cardiovascular Death
Cardiovascular death is defined by the underlying cause of death and will include death from acute MI, sudden cardiac death, heart failure, stroke, cardiovascular procedure, cardiovascular hemorrhage, and other cardiovascular causes. Cardiovascular death will be identified using claims data and the national death index.
Time frame: 5 years
Number of Participants with Nonfatal Myocardial Infarction
Participants with nonfatal myocardial infarction will be identified using claims data.
Time frame: 5 years
Number of Participants with Nonfatal Stroke
Participants with nonfatal stroke will be identified using claims data.
Time frame: 5 years
Started Jan 2019 (actual). Primary completion is estimated for Jun 2029, 125 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2030 → Jun 2029 and completion Nov 2030 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioDelivery Sciences International